← brief for 2026-08-30 · Slowing decline

Drug failure in diabetic kidney disease: translational barriers, target validation and trial de-risking strategies.

Article No results yet Peer reviewed

Key takeaways

This review asks why so many drugs for diabetic kidney disease fail in trials. It describes how standard care shifted away from just controlling sugar and blood pressure toward drugs that change the disease itself: RAAS blockers, SGLT2 inhibitors (the "flozin" pills), GLP-1 drugs, and a newer type of mineralocorticoid receptor blocker. The authors suggest ways to pick better drug targets and design safer trials. It is an opinion and summary piece, so it reports no new results.

Who did this work

Hu H · Hou S · Chen W · Hu J

Source

Article · PubMed, the drug frontier · 2026 Aug 29
https://pubmed.ncbi.nlm.nih.gov/42667964/